Firm will pay $1 million for rights to factor IX, factor VIII, and fibrinogen in the U.S., Europe, and Japan. GTC Biotherapeutics has exclusively licensed ProGenetics’ recombinant human factor IX, ...
-- Orphan drug designation provides marketing exclusivity if approved by FDA -- SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO) today announced ...
JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback